ALK IHC and FISH discordant results in patients with NSCLC and treatment response For discussion of the question - To treat or not to treat? - Université de Rennes Access content directly
Journal Articles European Society for Medical Oncology Year : 2018

ALK IHC and FISH discordant results in patients with NSCLC and treatment response For discussion of the question - To treat or not to treat?

Paul Hofman
M. Ilie
  • Function : Author
N. Peled
  • Function : Author
M. Hochmair
  • Function : Author
M. Dietel
  • Function : Author
M. von Laffert
  • Function : Author
F. Lopez-Rios
  • Function : Author
G. Erb
  • Function : Author
U. Schalles
  • Function : Author

Abstract

Introduction Lung cancer is the most common cancer worldwide. Latest guidelines from the College of American Pathologist and the European society of medical oncologists indicate anaplastic lymphoma kinase (ALK) rearrangement testing is standard practice. Historically, diagnostics for ALK used fluorescence in situ hybridisation (FISH); however, immunohistochemical (IHC) assays are becoming common practice. Unfortunately, recent assessment of current practice indicated that not all patients who should be tested for ALK translocation are undergoing ALK testing. Methods From a series of European and Israeli labs, we collected patients with discordant IHC and FISH testing, which were subsequently treated with ALK-targeted therapy, for discussion of the question, to treat or not to treat? Results Our study may support ALK IHC testing as a better predictor of response to targeted therapy provided that the labs implement controlled preanalytical procedures, use correct clone, run protocols on automated staining platforms and validate using external quality assessments. © Author (s) (or their employer(s)) 2018.

Keywords

Fichier principal
Vignette du fichier
e000419.full.pdf (312.03 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

hal-01905212 , version 1 (16-07-2019)

Identifiers

Cite

F. Cabillic, Paul Hofman, M. Ilie, N. Peled, M. Hochmair, et al.. ALK IHC and FISH discordant results in patients with NSCLC and treatment response For discussion of the question - To treat or not to treat?. European Society for Medical Oncology, 2018, 3 (6), pp.e000419. ⟨10.1136/esmoopen-2018-000419⟩. ⟨hal-01905212⟩
49 View
74 Download

Altmetric

Share

Gmail Facebook X LinkedIn More